Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262232 | PMC |
| http://dx.doi.org/10.1111/cts.12797 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.
NPJ Breast Cancer
January 2025
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Endocrine therapy with CDK4/6 inhibitors is standard for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), yet clinical resistance develops. Previously, we demonstrated that low doses of palbociclib activate autophagy, reversing initial G1 cell cycle arrest, while high concentrations induce off-target senescence. The autophagy inhibitor hydroxychloroquine (HCQ) induced on-target senescence at lower palbociclib doses.
View Article and Find Full Text PDFInnovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy.
Pharmaceutics
January 2025
Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. In this study, we introduce a novel lipid nanoparticle formulation co-delivering hydroxychloroquine (HCQ) and siRNA targeting TNF-α (si) using microfluidic technology, marking the first use of such a combination for RA therapy.
View Article and Find Full Text PDFLiposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.
Pharmaceutics
December 2024
Department of Experimental Therapeutics, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Preclinical studies have shown that the anti-malarial drug hydroxychloroquine (HCQ) improves the anti-cancer effects of various therapeutic agents by impairing autophagy. These findings are difficult to translate in vivo as reaching an effective HCQ concentration at the tumor site for extended times is challenging. Previously, we found that free HCQ in combination with gefitinib (Iressa, ZD1839) significantly reduced tumor volume in immunocompromised mice bearing gefitinib-resistant JIMT-1 breast cancer xenografts.
View Article and Find Full Text PDFBehçet's disease in pregnancy: a case report and literature review.
BMC Pregnancy Childbirth
January 2025
Department of Obstetrics and Gynecology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Longmatan Disrict, Chunhui Road 182, Luzhou, Sichuan, 646000, China.
Background: Behçet's disease (BD) during pregnancy is a relatively rare condition, and there are currently no established guidelines for its management. The effects of BD on both mothers and children remain unclear. In this paper, we present the diagnostic and treatment processes for a patient with BD during pregnancy.
View Article and Find Full Text PDFZebra bodies in lupus nephritis without Fabry disease or hydroxychloroquine therapy.
Kidney Res Clin Pract
January 2025
Department of Pathology, Binzhou Medical University Hospital, Binzhou, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!